<DOC>
	<DOCNO>NCT01721577</DOCNO>
	<brief_summary>This single-center , open-label , non-randomized , Phase I/IIa study investigate safety , tolerability , antitumor efficacy AXL1717 ( picropodophyllin active agent formulate oral suspension ; PPP ) patient recurrent malignant astrocytomas ( glioblastoma , gliosarcoma , anaplastic astrocytoma , anaplastic oligodendroglioma , anaplastic oligoastrocytoma , anaplastic ependymoma ) . Patients treat 5 cycle . A treatment cycle define 28 days+7 day rest ( 28+7 day cycle 1 4 , 28 day cycle 5 ) . The following cycle start treatment continuation criterion fulfil . Concomitant supportive therapy allow .</brief_summary>
	<brief_title>Phase I/II Trial Safety Anti-tumor Efficacy AXL1717 ( Picropodophyllin ) Treatment Recurrent Malignant Astrocytomas</brief_title>
	<detailed_description>AXL1717 , ready-to-use suspension picropodophyllin oral administration , distribute bottle single use concentration 25 mg/mL . Fixed dos use , i.e . adjustment weight body surface . There randomization blinding study . The trial divide two phase . In first phase , 10-20 patient enrol treated 300-520 mg BID AXL1717 28 day . The primary endpoint first phase determine recommend Phase 2 dose ( RP2D ) AXL1717 patient recurrent progressive glioblastoma ass safety toxicity AXL1717 patient population . The study 3+3 design first cohort treat 400 mg AXL1717 BID 28 day repeat 5 cycle . If dose-limiting toxicity ( DLT ) neutropenia occur , dose interrupt individual patient , follow normalization , restart low dose level accord standardized procedure . If two three first 3 patient specific dose level experience DLT first 28 day treatment AXL1717 , follow patient treat low dose level . If one DLT occur first 28 day dose first 3 three patient another 3 patient treat dose level . If 2 6 patient display DLT , next patient treat low dose level . The high dose level without DLT maximally one DLT 6 patient RPTD . All assessment respect dose adjustment subsequent cohort do first 28 day treatment . Non-progressing patient may treat total five 28-day cycle ( 24 week ) . In second phase , 12 patient enrol treated identified RP2D AXL1717 28 day repeat five cycle . The primary endpoint phase II ass proportion patient progression-free 24 week assess safety , tolerability , adverse event profile AXL1717 .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Ependymoma</mesh_term>
	<mesh_term>Oligodendroglioma</mesh_term>
	<mesh_term>Podophyllotoxin</mesh_term>
	<criteria>Inclusion criterion 1 . Be inform nature study provide write informed consent 2 . At least 18 year age 3 . ECOG performance 0 , 1 , 2 , KPS ( Karnofsky performance status ) ≥ 60 . 4 . Pathological verification WHO grade 4 astrocytoma ( glioblastoma gliosarcoma ) , WHO Grade 3 anaplastic astrocytoma , anaplastic oligodendroglioma , anaplastic oligoastrocytoma , anaplastic ependymoma . 5 . Documented recurrent glioblastoma , gliosarcoma , anaplastic astrocytoma , anaplastic oligodendroglioma , anaplastic oligoastrocytoma , anaplastic ependymoma least one fail treatment chemotherapy radiation 6 . Expected survival least 3 month 7 . At least 2weeks cytoreductive surgery , perform , 4weeks bevacizumab chemotherapy ( 6weeks prior chemotherapy nitrosourea ) 12weeks completion radiotherapy . 8 . Ability undergo MRI scan without image dye periodic basis define protocol 9 . Preserved major organ function , i.e : Blood leukocyte count ≥ 3.0 x 109/L Blood absolute neutrophil count ≥ 1.5 x 109/L Blood platelet count ≥ 100 x109/L Blood hemoglobin ≥ 100 g/L ( transfusion allow ) Plasma total bilirubin level ≤ 1.5 time upper institutional limit ( ULN ) ‖normal‖ ( i.e . reference ) range Plasma AST ( aspartate aminotransferase ) ALT ≤ 2.5 time upper institutional limit ( ULN ) ‖normal‖ range Plasma creatinine ≤ 1.5 time upper institutional limit ( ULN ) ‖normal‖ range 12lead ECG normal tracing ; change clinically significant require medical intervention , QTc &lt; 500 m At least seven ( 7 ) day medication inhibit induce CYP2C9 CYP3A4 first study treatment day Exclusion criterion 1 . Any major recent ongoing disease , accord Investigator , pose unacceptable risk patient 2 . Grade 3 high constipation within past 28 day grade 2 constipation within past 14 day randomization . ( Patients grade 2 constipation within past 14 day could rescreened constipation decrease ≤ grade 1 optimal management constipation . ) 3 . Coexisting uncontrolled medical condition . 4 . Hepatitis B Hepatitis C , HIV infection require antiretroviral therapy 5 . Active malignancy basal cell skin cancer 6 . Other active malignancy previous 3 year 7 . Major surgical procedure within 4 week 8 . Prior stereotactic gamma knife radiosurgery proton radiation , unless unequivocal progression functional neuroimaging ( PET , dynamic MRI , MRS , SPECT ) reoperation document histologic confirmation recurrence . 9 . Prior antitumor therapy , follow : least 12weeks radiation therapy ; least 4weeks prior treatment temozolomide bevacizumab , 6weeks BCNU CCNU . 10 . Women child bear potential ( WOCBP ) consent use acceptable method birth control ( oral contraceptive , IUD ) . For purpose study , WOCBP include female experienced menarche , undergone tubal ligation , postmenopausal . 11 . Medically uncontrolled Type 1 Type 2 diabetes mellitus 12 . Pregnancy lactation 13 . Current participation investigational clinical trial within 4weeks . 14 . Eastern Cooperative Oncology Group ( ECOG ) performance status &gt; 2 optimization medication ( See Appendix 4 ) KPS &lt; 60 15 . Anticipated Life expectancy le 3 month 16 . Contraindications investigational product know suspected hypersensitivity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>glioblastoma</keyword>
	<keyword>gliosarcoma</keyword>
	<keyword>anaplastic astrocytoma</keyword>
	<keyword>anaplastic oligodendroglioma</keyword>
	<keyword>anaplastic oligoastrocytoma</keyword>
	<keyword>AXL1717</keyword>
	<keyword>IGF-1 receptor inhibitor</keyword>
	<keyword>picropodophyllin</keyword>
</DOC>